Karyopharm (KPTI) CAO reports PSU vesting and small pre-planned tax sale

Rhea-AI Filing Summary

Karyopharm Therapeutics’ Chief Accounting Officer Kristin Abate reported a small set of routine equity transactions. On May 13, 2026, she acquired 121 shares of common stock at $0.00 per share from earned performance-based restricted stock units tied to completion of enrollment in the Company’s Phase 3 XPORT-EC-042 trial, which vested that day.

On May 14, 2026, 53 shares of common stock were sold at $9.50 per share in a broker-assisted transaction executed under a durable automatic sale instruction plan adopted on May 27, 2021, solely to satisfy withholding tax obligations from the PSU vesting, and not as a discretionary trade. After these transactions, Abate directly held 23,801 shares of Karyopharm common stock.

Insights

Equity compensation & insider-transactions analyst

Routine PSU vesting with small, pre-planned tax sale; net effect is minor.

The filing shows Kristin Abate, Karyopharm’s Chief Accounting Officer, receiving 121 shares via performance-based RSUs after a Phase 3 XPORT-EC-042 enrollment milestone was certified and the PSUs vested on May 13, 2026. This is standard equity compensation tied to clinical progress.

The subsequent sale of 53 shares at $9.50 on May 14, 2026 was executed under a durable automatic sale instruction plan adopted in May 2021 to cover withholding tax liability from the vesting, according to the footnote. Such tax-related, pre-planned sales carry limited informational value about insider sentiment.

Post-transaction, Abate directly holds 23,801 shares, indicating these movements are small relative to her position. The filing also notes prior purchases under the 2013 Employee Stock Purchase Plan, underscoring ongoing participation in company equity programs rather than a shift in exposure.

Insider Trade Summary

Net Seller: 53 shares ($504)

Net Sell 2 txns

Insider Abate Kristin

Role Chief Accounting Officer

Sold 53 shs ($503.50)

Type	Security	Shares	Price	Value
Sale	Common Stock	53	$9.50	$503.50
Grant/Award	Common Stock	121	$0.00	--

Holdings After Transaction: Common Stock — 23,801 shares (Direct, null)

Footnotes (1)

1. Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026. Includes 1,670 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan, as amended, on April 30, 2026. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

Key Figures

Shares sold: 53 shares Sale price: $9.50 per share PSU shares vested: 121 shares +3 more

6 metrics

Shares sold 53 shares Open-market sale at $9.50 on May 14, 2026

Sale price $9.50 per share Broker-assisted sale to cover tax withholding

PSU shares vested 121 shares Earned PSUs vesting on May 13, 2026

Shares held after transactions 23,801 shares Direct Karyopharm common stock ownership after May 2026 trades

ESPP shares included 1,670 shares Acquired under 2013 Employee Stock Purchase Plan on April 30, 2026

Net shares sold 53 shares Net sell direction from transaction summary

Key Terms

performance-based restricted stock units, Phase 3 XPORT-EC-042 trial, durable automatic sale instruction plan, withholding tax liability, +1 more

5 terms

performance-based restricted stock units financial

"Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024..."

Performance-based restricted stock units are a type of employee equity award that converts into company shares only if predefined financial or operational targets are met over a set period. Think of it like a bonus check that becomes stock only when specific goals are hit; it ties pay to results, aligning managers’ incentives with shareholders. Investors care because these awards affect future share count, executive incentives, and signal how management’s success will be measured and rewarded.

Phase 3 XPORT-EC-042 trial medical

"...based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial..."

durable automatic sale instruction plan financial

"This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021..."

withholding tax liability financial

"...represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs."

Employee Stock Purchase Plan financial

"Includes 1,670 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan, as amended..."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Abate Kristin

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MASSACHUSETTS 02459

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/13/2026		A		121(1)	A	$0.0	23,854(2)	D
Common Stock	05/14/2026		S(3)		53	D	$9.5	23,801	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026.

2. Includes 1,670 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan, as amended, on April 30, 2026.

3. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

	/s/ Nancy Smith as Attorney-in-Fact for Kristin Abate	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Karyopharm (KPTI) CAO Kristin Abate report?

Kristin Abate reported two transactions: a grant of 121 Karyopharm common shares from earned performance-based restricted stock units, and a sale of 53 shares at $9.50 each. The sale was executed solely to cover tax withholding from the PSU vesting under an automatic plan.

Why did Karyopharm (KPTI) CAO sell 53 shares on May 14, 2026?

The 53-share sale at $9.50 was a broker-assisted transaction executed under a durable automatic sale instruction plan adopted in May 2021. The footnote states it was solely to satisfy withholding tax liability from PSU vesting and was not a discretionary trade by Abate.

What triggered the performance-based RSU vesting for Karyopharm (KPTI) CAO?

The vesting was triggered when performance-based restricted stock units granted in February 2024 were earned after achieving a clinical milestone: complete enrollment in the Phase 3 XPORT-EC-042 trial. Karyopharm’s Compensation Committee certified this milestone on May 13, 2026, and the earned PSUs vested that same day.

How many Karyopharm (KPTI) shares does Kristin Abate hold after these transactions?

Following the May 2026 transactions, Kristin Abate directly holds 23,801 shares of Karyopharm common stock. A footnote also notes that this amount includes 1,670 shares she acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2026.

Were the Karyopharm (KPTI) insider transactions linked to options or derivative exercises?

No derivative securities are reported in this filing. The transactions involve non-derivative Karyopharm common stock: 121 shares from earned performance-based restricted stock units that vested, and 53 shares sold to cover withholding taxes, with no option exercises or other derivative activity disclosed.